New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
16:39 EDTAET, ZLC, VVUS, STJ, SQNM, CRM, TLYSOn The Fly: Closing Wrap
Stocks on Wall Street were higher on the day, the last full trading session of the week ahead of Thursday's holiday and Friday's half day. Jobless data that was in-line with expectations did little to move the markets before the open, but the markets slowly moved higher through the session, although volume remained light. Just after midday, news crossed that a cease fire between Israel and Hamas had been reached, tempering fears that the conflict could escalate to involve other players in the region and have broader economic impacts... ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 410,000, which was in-line with forecasts. Markit's "flash" November flash PMI rose to 52.4 from 51.0 in October. The final November reading of the University of Michigan Sentiment index slipped to 82.7 from its 84.9 preliminary reading. The leading indicators edged up 0.2% in October to 96.0 from 95.8 in September. In Europe, the region's finance ministers and the IMF were unable to reach a bailout agreement for Greece and will meet again on Monday with an eye on resolving the remaining disagreements. In Asia, Japanese exports fell 6.5% in October, lower than expectations for a 4.9% decline... COMPANY NEWS: Salesforce.com's (CRM) Q3 results beat on the top and bottom lines and RW Baird and Wells Fargo reiterated their Outperform ratings on the stock following the report, and shares of Salesforce.com traded higher on the session, settling up $12.88, or 8.83%, to $158.78... MAJOR MOVERS: Among notable gainers were shares of VIVUS (VVUS), up $1.38, or 13.33%, to $11.73 after Aetna (AET) posted a policy revision that expands coverage of the company's weight-loss drug Qsymia. Also higher were shares of Sequenom (SQNM), up 56c, or 15.18%, to $4.25 after a committee of the American College of Obstetricians and Gynecologists recommended that cell-free fetal DNA testing be offered to certain at-risk patients. Among the noteworthy were shares of Zale (ZLC), down over $2.23, or 29.97%, to $5.21, and Tilly's (TLYS), down $2.69, or 17.18%, to $12.97 after reporting earnings. Also lower were shares of St. Jude Medical (STJ), which fell $4.34, or 12.15%,to $31.37 after an FDA inspection report cited serious flaws in its oversight of design changes in its Durata line of defibrillator leads... INDICES The Dow was up 48.38, or 0.38%, to 12,836.89; the S&P 500 was up 3.22, or 0.23%, to 1,391.03;the Nasdaq was up 9.87, or 0.34%, to 2,926.55.
News For CRM;VVUS;AET;SQNM;ZLC;TLYS;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 18, 2015
07:24 EDTCRMSalesforce buyout rumors may cloud earnings focus, says Susquehanna
Subscribe for More Information
May 15, 2015
16:51 EDTAETGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
May 14, 2015
09:41 EDTSTJLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:21 EDTCRMSalesforce price target raised to $87 from $78 at Goldman
Subscribe for More Information
06:21 EDTCRMSalesforce implied volatility of 57 at upper end of index
Subscribe for More Information
May 13, 2015
10:18 EDTAETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
08:08 EDTSTJSt. Jude Medical receives CE Mark approval of Ellipse expanded labeling
Subscribe for More Information
07:31 EDTSTJHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
16:33 EDTCRMSalesforce, Sage announce strategic partnership, new small business platform
Subscribe for More Information
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTAETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
11:38 EDTCRMLivePerson sinks to 52-week low after cutting fiscal 2015 outlook
Shares of LivePerson (LPSN), a provider of cloud-based digital engagement solutions, are sinking after the firm lowered its outlook for fiscal 2015. WHAT'S NEW: LivePerson yesterday reported first quarter adjusted earnings per share of 4c, in line with analysts' consensus estimates, on revenue of $59.8M, slightly below analysts' consensus estimates of $60.79M. LivePerson said it signed 147 deals in the quarter, including the addition of 30 new customers. Looking ahead to the second quarter, LivePerson forecast adjusted EPS of 0c-2c and revenue of $58.5M-$59.5M, well below the analysts' consensus estimates of 6c and $63.88M, respectively. WHAT'S NOTABLE: The company lowered its fiscal year 2015 adjusted EPS view to 10c-15c from 27c-32c, significantly trailing analysts' consensus estimates of 28c. LivePerson also cut its FY15 revenue outlook to $243M-$247M from $263M-$269M, also well below analysts' estimates of $264.36M. The company reduced reduced FY15 revenue guidance by $21M when comparing the midpoint of its updated guidance range to the midpoint of its previous guidance range. The adjustment reflects the impact of one large customer contract that ended, an increase in foreign exchange headwinds and a slightly slower start to the year than expected as the company intensified its focus on bringing LiveEngage to the market, the company said. LivePerson said it expects to record a $2.5M charge in Q2 related to cost-cutting move, which it described as "reprioritizing on areas showing the highest potential growth." The company believes its cost-savings initiatives will generate approximately $13M of expense savings in 2015. ANALYST REACTION: Credit Suisse this morning downgraded LivePerson to Neutral from Outperform and lowered its price target to $8 from $19. The firm said LivePerson was "forced" to lower revenue guidance for FY15 primarily due to the loss of AT&T (T) as a pay-for-performance chat customer, as well as from a slow sales start and FX. The firm said the ability of LivePerson to transition its large customer base to LiveEngage 2.0 will take longer than previously estimated. PRICE ACTION: In late morning trading, LivePerson fell $1.16, or 12.26%, to $8.30 on more than five times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $8.10. Including today's pull back, the shares have lost approximately 15% over the past 12 months. OTHERS TO WATCH: Other companies offering cloud-based digital engagement solutions include eGain (EGAN), down 1.2%, Zendesk (ZEN), down 4.05%, and Salesforce.com (CRM), up 0.2%.
10:04 EDTAETHigh option volume stocks
Subscribe for More Information
09:53 EDTAETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
07:35 EDTSTJBofA/Merrill to hold a conference
Subscribe for More Information
06:02 EDTCRMSalesforce implied volatility of 64 at upper end of index
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use